Verrica Pharmaceuticals Inc (FRA:1NE)
€ 0.593 -0.0645 (-9.81%) Market Cap: 59.47 Mil Enterprise Value: 82.64 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 33/100

Verrica Pharmaceuticals Inc to Host KOL Event (Virtual) Transcript

Oct 11, 2023 / 03:00PM GMT
Release Date Price: €3.54 (-4.84%)
Unidentified Participant

Good morning and welcome to the Verrica Pharmaceuticals KOL Investor Event. (Event Instructions)

As a reminder, this call is being recorded and a replay will be made available on the Verrica following the conclusion of the event.

I'd now like to turn the call over to Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals. Please go ahead, Ted.

Ted White
Verrica Pharmaceuticals Inc. - President, CEO

Thank you, [Tara]. Good morning, everyone. I'd like to personally welcome you and thank everyone for participating in today's virtual KOL Investor Event discussing our recent FDA approval of YCANTH, the first and only approved treatment for molluscum contagiosum in adult and pediatric patients, two years of age and older.

Molluscum is caused by a pox virus that produces a distinct raised skin-toned-to-pink-colored lesions that can cause pain, inflammation, itching, and bacterial infections. It's easily transmitted through direct skin-to-skin contact or through fomites and can spread to other parts of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot